- $4.81m
- $45.28m
- $20.76m
Brief: Dss Reports Going Concern Audit Opinion In 2025 10-K Filing
Brief: Dss Inc Actively Evaluating Acquisition Opportunities Within Folding Carton Space
Brief: Dss, Inc. Announces Pricing Of $1.0 Million Underwritten Public Offering
Brief: DSS’s Subsidiary, Impact Biomedical, Announces Strategic Merger
Brief: DSS Frank D. Heuszel To Step Down As CEO
Brief: DSS Inc Executes A Letter Agreement With CEO Frank Heuszel
Brief: DSS Inc's Unit Secures Contract Extension With Major Retailer Worth Up To $15 Mln Over Four Years
Brief: DSS Discloses Reverse Split of Outstanding, Issues Common Stock
Brief: Dss Inc. Receives Notice Of Non-Compliance With NYSE American Trading Share Price Listing Rule
Brief: DSS Inc Announces Filing Of Registration Statement On Form S-1 For IPO Of Its Unit, Impact Biomedical
Brief: DSS Inc Announces Distribution Date Of August 8 For Spinoff Of Impact Biomedical
Brief: DSS Receives New York Stock Exchange Notice Regarding Late Form 10-Q Filing
Brief: DSS Inc - Impact BioMedical Develops Quantum Antihistamine
Document Security Solutions rises on licensing deal with ProPhase Labs
Brief: DSS Announces Licensing Of Impact Biomedical’s Linebacker Portfolio To Prophase Labs
Brief: Impact Biomedical Announces License Agreement With Prophase Labs To Produce And Distribute Viral-Fighting Compound Equivir
Brief: DSS’s Impact Biomedical Receives China Patent For Its Functional Fragrance Formulation Mosquito Repellant
Brief: Impact Biomedical's Proprietary Equivir Compound To Treat Viral Infection Receives Clean Patentability Report From World Intellectual Property Organization's Isa Division
AMEX RESUMED DSS INC ORD